SynthesisFrontiers in medicine2026
Perfluorocarbon-based artificial oxygen carriers in perioperative and surgical care: a scoping review of basic and translational studies.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Perioperative hypoxia remains a common clinical complication. Allogeneic blood transfusion and conventional oxygen support are widely used but limited by blood shortage, supply constraints and ethical challenges. Perfluorocarbon-based oxygen carriers (PFCs) possess superior oxygen solubility and favorable physicochemical features, making promising candidate adjuncts to improve perioperative oxygenation, despite multiple unresolved translational drawbacks. Methods: This scoping review strictly followed the PRISMA-ScR standard. Six mainstream databases were systematically searched for English human and animal studies published from 2000 to 2025 focusing on perioperative and surgical applications of PFCs; eligible literature was screened and data extracted based on predefined criteria. Results: A total of 55 publications including 13 randomized controlled trials were enrolled. Preclinical and clinical data demonstrated PFC effectively improves tissue oxygenation and organ protection across hemorrhagic shock, brain injury and acute lung injury, with the most consistent therapeutic gains observed in organ preservation. PFC can reduce allogeneic transfusion requirements during major surgery and benefit cerebral ischemia management, while inflammatory side effects, thrombocytopenia and other adverse reactions have been repeatedly documented. Conclusion: PFCs show encouraging tissue-protective effects particularly in organ preservation, yet its broad clinical translation is hindered by inherent limitations such as high oxygen dependence, CARPA, reticuloendothelial deposition and historical failure of classic formulations. Further optimized formulation design and large-scale clinical trials are mandatory to improve safety and realize targeted clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.